JP2023519562A - サルモネラに基づく新規コロナウイルスワクチン - Google Patents

サルモネラに基づく新規コロナウイルスワクチン Download PDF

Info

Publication number
JP2023519562A
JP2023519562A JP2022556158A JP2022556158A JP2023519562A JP 2023519562 A JP2023519562 A JP 2023519562A JP 2022556158 A JP2022556158 A JP 2022556158A JP 2022556158 A JP2022556158 A JP 2022556158A JP 2023519562 A JP2023519562 A JP 2023519562A
Authority
JP
Japan
Prior art keywords
cov
sars
protein
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519562A5 (enExample
Inventor
ルベナウ ハインツ
マンスール マーク
Original Assignee
エンエーセー オンコイミュニティ アクスイェ セルスカプ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンエーセー オンコイミュニティ アクスイェ セルスカプ filed Critical エンエーセー オンコイミュニティ アクスイェ セルスカプ
Publication of JP2023519562A publication Critical patent/JP2023519562A/ja
Publication of JP2023519562A5 publication Critical patent/JP2023519562A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022556158A 2020-03-31 2021-03-31 サルモネラに基づく新規コロナウイルスワクチン Pending JP2023519562A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20167405.8 2020-03-31
EP20167405 2020-03-31
PCT/EP2021/058513 WO2021198376A1 (en) 2020-03-31 2021-03-31 Novel salmonella-based coronavirus vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026077196A Division JP2026131609A (ja) 2020-03-31 2026-05-01 サルモネラに基づく新規コロナウイルスワクチン

Publications (2)

Publication Number Publication Date
JP2023519562A true JP2023519562A (ja) 2023-05-11
JP2023519562A5 JP2023519562A5 (enExample) 2024-04-08

Family

ID=70110247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556158A Pending JP2023519562A (ja) 2020-03-31 2021-03-31 サルモネラに基づく新規コロナウイルスワクチン

Country Status (8)

Country Link
US (1) US20230137174A1 (enExample)
EP (1) EP4126022A1 (enExample)
JP (1) JP2023519562A (enExample)
KR (1) KR20220161444A (enExample)
CN (1) CN115715198A (enExample)
AU (1) AU2021250442A1 (enExample)
CA (1) CA3170674A1 (enExample)
WO (1) WO2021198376A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550004A (ja) * 2020-11-20 2023-11-30 北京震旦鼎泰生物科技有限公司 融合遺伝子、組換え新型コロナウイルス高効率免疫ｄｎａワクチン、それらの構築方法及び使用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39378A (es) * 2020-08-14 2022-01-31 Univ Wuerzburg J Maximilians Vacuna de salmonella para el tratamiento de coronavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1686563A (zh) * 2005-03-30 2005-10-26 武汉大学 一种染色体上携带病毒基因的减毒伤寒杆菌疫苗及制备方法
US20060240515A1 (en) * 2003-07-21 2006-10-26 Dimitrov Dimiter S Soluble fragments of the SARS-CoV spike glycoprotein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1654364A4 (en) * 2003-08-13 2008-02-13 Novartis Vaccines & Diagnostic CURRENT HOST CELL RELEASE COMPRISING POLYNUCLEOTIDES ENCODING IMMUNOGENS
BR112014015706A2 (pt) 2011-12-22 2020-10-27 Vaximm Ag método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a
WO2018213242A1 (en) * 2017-05-15 2018-11-22 University Of Maryland, Baltimore Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
WO2020237246A1 (en) * 2019-05-23 2020-11-26 University Of Maryland, Baltimore Live attenuated non-transmissible vaccines
US10973908B1 (en) * 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240515A1 (en) * 2003-07-21 2006-10-26 Dimitrov Dimiter S Soluble fragments of the SARS-CoV spike glycoprotein
CN1686563A (zh) * 2005-03-30 2005-10-26 武汉大学 一种染色体上携带病毒基因的减毒伤寒杆菌疫苗及制备方法

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CLINICAL AND VACCINE IMMUNOLOGY, vol. 14, no. 7, JPN6025011335, 2007, pages 894 - 901, ISSN: 0005656695 *
CLINICAL AND VACCINE IMMUNOLOGY, vol. 14, no. 8, JPN6025011339, 2007, pages 990 - 997, ISSN: 0005656689 *
CLINICALTRIALS: "NCT04283461", [ONLINE], JPN6025031969, 26 March 2020 (2020-03-26), ISSN: 0005656698 *
IMMUNOLOGY AND CELL BIOLOGY, vol. 87, JPN6025011337, 2009, pages 400 - 412, ISSN: 0005656691 *
NATURE, vol. 579, JPN6025011334, 2020, pages 265 - 269, ISSN: 0005656694 *
SCI REP, vol. 8:15701, JPN6025011338, 2018, pages 1 - 11, ISSN: 0005656692 *
SCIENCE, vol. 367, no. 6483, JPN6025031968, 13 March 2020 (2020-03-13), pages 1260 - 1263, ISSN: 0005656696 *
SYED FARAZ AHMED ET AL.: ""Preliminaryidentification of potential vaccine targets for the COVID-19 coronavirus(SARS-CoV-2) ba", UNDEFINED, JPN6025031971, 12 February 2020 (2020-02-12), ISSN: 0005656690 *
VACCINE, JPN6025011333, 2005, pages 4959 - 4968, ISSN: 0005656693 *
VACCINES, vol. Vol. 8, No. 2, 153, JPN6025031970, 29 March 2020 (2020-03-29), ISSN: 0005656697 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550004A (ja) * 2020-11-20 2023-11-30 北京震旦鼎泰生物科技有限公司 融合遺伝子、組換え新型コロナウイルス高効率免疫ｄｎａワクチン、それらの構築方法及び使用
JP7686302B2 (ja) 2020-11-20 2025-06-02 北京震旦鼎泰生物科技有限公司 融合遺伝子、組換え新型コロナウイルス高効率免疫ｄｎａワクチン、それらの構築方法及び使用

Also Published As

Publication number Publication date
US20230137174A1 (en) 2023-05-04
CA3170674A1 (en) 2021-10-07
KR20220161444A (ko) 2022-12-06
EP4126022A1 (en) 2023-02-08
CN115715198A (zh) 2023-02-24
AU2021250442A1 (en) 2022-11-10
WO2021198376A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CN113151184B (zh) 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法
WO2020063370A2 (zh) 免疫组合物及其制备方法与应用
WO2021160346A1 (en) Nucleic acid vaccine against the sars-cov-2 coronavirus
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
JP7731670B2 (ja) ネコ白血病ウイルスワクチン
US10836809B2 (en) Mosaic chimeric viral vaccine particle
US20230174588A1 (en) A vaccine against sars-cov-2 and preparation thereof
EP4205762A1 (en) Improved dna vaccine for sars-cov-2
WO2022003119A1 (en) Cross-reactive coronavirus vaccine
WO2023023940A1 (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
KR20240019213A (ko) 코로나바이러스를 위한 바이러스 유사 입자 백신
US20230137174A1 (en) Novel salmonella-based coronavirus vaccine
US20220211839A1 (en) Feline leukemia virus vaccine
WO2022105880A1 (zh) 融合基因及一种重组新型冠状病毒高效免疫dna疫苗及其构建方法和应用
Agterberg et al. Outer membrane protein PhoE as a carrier for the exposure of foreign antigenic determinants at the bacterial cell surface
US20180153976A1 (en) Novel cmv pp65 targeting dna vaccine for cancer immunotherapy
US20250186575A1 (en) Vaccine construct and uses thereof
WO2025189435A1 (zh) 针对猫fipv的多表位抗原构建rna疫苗的方法
US20240181041A1 (en) Adenovirus SARS-CoV-2 Vaccine
CN113278634B (zh) 一种预防和治疗默克尔细胞癌的新型疫苗
KR102646366B1 (ko) 바이러스 유사 입자를 이용한 돼지 유행성 설사병 바이러스 백신 및 이의 제조방법
Choudary et al. Enhanced immune response of DNA vaccine (VP1-pCDNA) adsorbed on cationic PLG for foot and mouth disease in guinea pigs
JP4535874B2 (ja) 肝炎に対するバクテリオファージを介する免疫
WO2025189436A1 (zh) 针对猫fipv的多表位抗原构建环状rna疫苗的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260501